Prostate cancer in 2011: Hitting old targets better and identifying new targets

Nature Reviews Clinical Oncology

Volumn 9, Issue 2, 2012, Pages 70-72

  Chen, Yu ^a   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; CABAZITAXEL; CABOZANTINIB; DASATINIB; DENOSUMAB; DOCETAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATECTOMY; REVIEW;

CLINICAL TRIALS AS TOPIC; HISTORY, 21ST CENTURY; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS;

EID: 84862790530     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.213     Document Type: Review

References (10)

1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47, a7003 (2011).
3. Medivation. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer [online], http://investors.medivation.com/releasedetail.cfm? releaseid=620500 (2011).
4. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
5. Yu, E. Y. et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7421-7428 (2009).
6. Hussain, M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract]. J. Clin. Oncol. 29 (Suppl.), a4516 (2011).
7. Hugosson, J. et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-732 (2010).
8. Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
9. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
10. Chou, R. et al. Screening for prostate cancer: a review of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med. 155, 762-771 (2011).